Overview

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2018-02-19
Target enrollment:
Participant gender:
Summary
This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals